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Abstract
The pharmacokinetics of isoniazid (INH) and rifampicin (RMP) was determined in 22 renal failure patients, 11 each
with low and high membrane permeabilities (LMP and HMP) undergoing Continuous Ambulatory Peritoneal Dialysis
(CAPD). Blood samples were collected at different time points following oral administration of INH and RMP. Estimations
of INH and RMP in blood were carried out by standard procedures and certain pharmacokinetic variables were
calculated based on their concentrations in blood. The INH inactivation status was determined based on salivary levels
of INH. The pharmacokinetic variables of INH and RMP did not differ significantly between LMP and HMP groups. The
study results suggest that renal failure patients on CAPD may not require reduction in the dosage of RMP or INH in rapid
acetylators. Slow acetylators might require dose reduction of INH.  Determination of INH inactivation status is important
when patients with renal failure and tuberculosis are treated with INH-containing regimens.
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Introduction
Drugs are eliminated from the body by metabolism and
excretion. The kidneys play a major role in the excretion
of drugs and/or their metabolites. When they fail, such
substances may accumulate and cause unwanted side
effects. Therapeutic doses as administered to patients
with normal renal function could lead to sustained high
plasma levels in patients with renal failure and this could
be toxic.
We have earlier demonstrated that in patients with
chronic renal failure, the dosage of INH may be reduced
in slow acetylators of the drug1. However, the same may
not be applicable to renal failure patients undergoing
CAPD. Information on the pharmacokinetics of anti-
tuberculosis (TB) drugs is therefore essential in renal
failure patients undergoing CAPD, so that drug dosages
can be appropriately adjusted. No information is available
to the best of our knowledge, on the pharmacokinetics
of INH in such patients except for a study report on RMP
carried out in two subjects2. We, therefore, studied single
dose pharmacokinetics of two first-line anti-TB drugs,
namely, RMP and INH in patients with end stage renal
failure on CAPD having different peritoneal permeability.
Methods
Subject: A total of 22 patients comprising of 13 males
and 9 females who were undergoing treatment at the
Nephrology Unit of Apollo Hospitals, Chennai were
recruited to the study. All the study subjects were suffering
from end stage renal failure and were undergoing CAPD.
The patients were classified as having LMP or HMP
based on peritoneal equilibration test. Those patients
who had low or low average were classified as low
peritoneal membrane permeability (LMP), and those with
high or high average were classified as high membrane
permeability (HMP). Patients in the LMP group received
3 exchanges of 2 litres, 8 hours dwell time; while patients
in HMP group received 3 exchanges of 2 litres, 3-4 hours
dwell time. The hepatic function, as assessed by liver
function tests, was normal in all the patients. They were
not suffering from any other ailment except renal failure
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Table1 Dosage schedule:
Body-weight range (kg) Isoniazid (mg) Rifampicin (mg)
<30 200 300
30.0 – 44.9 300 450
45.0 – 59.9 400 600
> 60.00 500 750
The study was cleared by the Ethics Committees of the
Tuberculosis Research Centre and Apollo Hospitals,
Chennai. The nature of the study and possible side
effects of the drugs were explained to the patients and
informed written consent was obtained from them before
they took part in the study.
Determination of acetylator phenotype
Prior to start of the study, the INH acetylator status was
determined in all eligible patients according to the
method of Kailasam et al.3. A uniform oral dose of INH
(100mg) was administered and a sample of saliva was
collected exactly at 5 hours after drug administration.
The concentration of INH in saliva was determined
according to the method of Gurumurthy et al.4. The
criterion for a slow acetylator was taken as a
concentration of INH e” 0.41 µg/ml.
Conduct of Study
On the day of the investigation, INH (7.5 mg/kg) and RMP
(12 mg/kg) (according to the dosage schedule in Table
1) were administered on an empty stomach and blood
samples were collected at 1,2,3,6, and 8 hours in
heparinised containers. Plasma was separated from all
the blood samples and stored at –20oC until drug
estimations were carried out.
Plasma concentrations of INH were determined by the
spectrofluorimetric method of Olson et. al. 5, and of RMP
by the plate diffusion method of Dickinson et al. 6. All the
specimens were coded before drug estimations were
undertaken.
Pharmacokinetic and Statistical Analysis: On each series
of plasma INH and RMP concentrations, certain
pharmacokinetic variables were calculated. Maximum
concentrations (Cmax) and the time to attain Cmax (Tmax)
were determined by direct visual inspection of data. The
linear trapezoidal rule was used to compute the exposure
or area under the time concentration curve (AUC); the
elimination rate constant (Kel) was calculated from the
terminal log-linear decline of concentration; the terminal
elinination half-life (t½) was calculated as 0.693/Kel; and
AUCo-α was calculated by adding the sum of AUC
obtained from time zero until 8 hour concentration to the
last quantifiable concentration (at 8 hours) divided by Kel.
The plasma clearance (Cl) was calculated as dose/
AUCo-α.
The pharmacokinetic values were expressed as mean
± standard deviation. Student’s t-test (unpaired) was
employed for testing the differences between the mean
values of the LMP and HMP groups and the significance
was taken at the 5% level.
Results
A total of 22 patients comprising of 13 males and 9
females were admitted to the study. Among them, 11 each
belonged to the LMP and HMP groups. The mean age
and body weight of the patients having LMP were 45.2
years (10-72 years) and 59.3 kg (24-90 kg) respectively.
The corresponding values in patients having HMP were
49.8 years (16-67 years) and 58.1 kg (37-86 kg).
The mean dosages of INH administered to patients with
LMP and HMP were 7.11 and 7.40 mg/kg bodyweight
respectively, while the corresponding values for RMP
were 10.69 and 11.20 mg/kg body weight. The numbers
of slow and rapid acetylators of INH among patients with
LMP were seven and four and with HMP were six and
five respectively.
The distribution of patients having LMP and HMP
according to the time at which the highest plasma
concentrations of INH (amalgamating the findings in slow
and rapid acetylators) and RMP were attained is
presented in Table 2. The rate of gastro-intestinal
absorption of INH appears to be similar in both the groups
of patients as evident from the fact that in majority of the
patients, peak concentrations were attained within one
hour. However, in the case of RMP, there appeared to be
a delay in the absorption in patients having HMP
compared with that of LMP.
The mean serial plasma INH and RMP concentrations
between LMP and HMP groups of patients did not show
any statistical significance at all the time points tested.
The pharmacokinetic variables calculated based on
plasma concentrations of INH and RMP were not
different between the LMP and HMP groups (Tables 3
and 4).
SAARC Journal of Tuberculosis, Lung Diseases & HIV/AIDS 25
Discussion
Isoniazid is eliminated from the system by acetylation as
well as renal excretion. While elimination of the drug is
predominantly through acetylation in rapid acetylators,
approximately equal proportions are eliminated through
acetylation and renal excretion in slow acetylators7.
Therefore, exposure and elimination half-life are
expected to be higher in slow acetylators. Several studies
conducted previously at our centre, both in healthy
subject and in patients with pulmonary and extra
pulmonary TB have reported half-lives ranging from 2.8
to 3.4 hours for slow and 1.2 to 1.9 hours for rapid
acetylators of INH1, 4, 8-10. The present study shows that,
despite patients undergoing dialysis, plasma
concentrations of INH in slow acetylators lead to higher
half-life in LMP and HMP groups of patients. However,
the mean C
max
 and AUC values in slow acetylators were
Table 2 Distribution of patients based on peak concentrations of isoniazid and rifampicin
Group Drug                 No. of subjects with peak concentrations observed at
1 h 2 h 3 h 6 h 8 h
LMP Isoniazid 6 1 4 - -
n=11 Rifampicin 3 5 3 - -
HMP Isoniazid 6 5 - - -
n=11 Rifampicin 2 2 6 1 -
LMP – Low membrane permeability, HMP – High membrane permeability
Table 3 Pharmacokinetics of Isoniazid in patients with different membrane permeability:
Pharmacokinetic Mean µ SD
Variables Slow Rapid
% LMP(n=7) HMP(n=6) LMP(n=4) HMP (n=5)
Peak Concentration 11.73 ± 2.15 11.71±2.07 7.17±2.51 10.43±5.32
(µg/ml)
Exposure          (0-8) 69.09±13.85 61.17±11.75 22.65±9.03 34.49±16.80
(µg/ml.hours) (0-  ) 213.47±55.89 139.39±28.00 25.78±11.64 38.83±19.84
Clearance (ml/min) 6.51±1.12 7.28±1.67 18.36±13.71 15.00±8.13
Half-life (hours) 8.16±1.23 6.15±1.04 2.42±0.75 2.46±0.12
LMP-Low membrane permeability, HMP – High membrane permeability
Table 4 Pharmacokinetics of rifampicin in patients with different membrane permeability:
Pharmacokinetic                          Mean µ SD
Variables       LMP (n=11)       HMP(n=11)
Peak Concentration (µg/ml) 10.37±4.21 10.44±4.00
Exposure          (0-8) 56.49±24.73 50.90±20.37
(µg/ml.hours)    (0-  ) 172.51±82.11 193.19±127.14
Clearance (ml/min) 12.35±4.67 15.61±12.99
Half-life (hours) 6.92±2.05 6.35±1.68
LMP-Low membrane permeability, HMP – High membrane permeability
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almost similar to our previous data 1, 4, 8-10. The elimination
of INH in rapid acetylators did not seem to be affected. It
may therefore be advisable to reduce the dosage of INH
in slow acetylators with renal failure undergoing CAPD.
However, with respect to rapid acetylators of INH, since
the pharmacokinetic variables obtained in this study
were almost similar to our previous study data, it may not
be necessary to adjust drug dosages. This emphasizes
the need to determine the INH acetylator status of patients
suffering from renal failure and TB, and who require
treatment with INH-containing regimens.
Methods to determine INH acetylator status in renal failure
patients based on urinary excretion of acetyl INH and
INH are obviously not suitable. On the other hand,
estimating INH in saliva, collected at a particular time-
point, as done in this study can be used to determine the
acetylator phenotype in adults3 as well as in children11.
Our recommendation with respect to the dosage of INH
in patients with renal failure particularly with the slow
acetylators is not in line with that of Reidenberg et. al.12
who in their investigation of eight patients with renal
failure did not find a need to reduce the dosage of this
drug. A study conducted by Bowersox et. al13 in 10
patients with chronic renal failure did not recommend
reduction in the dose of INH (300mg) in rapid and slow
acetylators with serum creatinine concentration less than
12 mg/dl. Neither of the investigators had classified
patients as slow or rapid acetylators.
The elimination of RMP is mainly through hepato-biliary
excretion14, with kidneys playing only a minor role. This
is evident from this study data where we did not observe
any difference in the pharmacokinetic variables between
patients with renal failure undergoing CAPD and our
previous study data1, 4, 8-10. Also no differences were
observed in patients having different membrane
permeability. These findings suggest that there is no need
to reduce the dosage of RMP in patients with renal failure
undergoing CAPD. This is in agreement with that reported
previously in patients with severe renal failue1 and also
by Woo et. al 2 who observed that in patients with TB on
maintenance dialysis, the dosage of RMP need not be
reduced.
The risk of developing pulmonary and extra pulmonary
TB is increased in patients undergoing peritoneal
dialysis, especially in Asia 7, 15, 16. Since very scanty
information is available on the pharmacokinetics of INH
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